TG Therapeutics, Inc. (TGTX Quick QuoteTGTX - Free Report) was a big mover last session, as the company saw its shares rise over 9% on the day. The company announced that the U.S. Food and Drug Administration has granted orphan drug designation for its oral, next generation PI3K Delta inhibitor, TGR-1202. The news led to far more shares changing hands than in a normal session resulting in solid volume. This breaks the recent trend of the company, as the stock is now trading above the volatile price range of $5.49 to $6.39 in the past one-month time frame.

The company has seen a mixed track record when it comes to estimate revisions of one increase and four decreases over the past one month, while the Zacks Consensus Estimate moved lower over the same time frame. Yesterday’s price action is encouraging though, so make sure to keep a close watch on this stock in the near future.

TG Therapeutics currently carries a Zacks Rank #3 (Hold), while its Earnings ESP is 0.00%.

TG THERAPEUTICS Price

TG THERAPEUTICS Price | TG THERAPEUTICS Quote

A better-ranked stock in the same industry is GW Pharmaceuticals plc , sporting a Zacks Rank #1 (Strong Buy).

Is TGTX going up? Or down? Predict to see what others think: Up or Down

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>